Silvia Gentili

1.2k total citations
32 papers, 450 citations indexed

About

Silvia Gentili is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Silvia Gentili has authored 32 papers receiving a total of 450 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 22 papers in Molecular Biology and 22 papers in Oncology. Recurrent topics in Silvia Gentili's work include Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (18 papers) and Peptidase Inhibition and Analysis (12 papers). Silvia Gentili is often cited by papers focused on Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (18 papers) and Peptidase Inhibition and Analysis (12 papers). Silvia Gentili collaborates with scholars based in Italy, Netherlands and Germany. Silvia Gentili's co-authors include Massimo Offidani, Laura Corvatta, Pietro Leoni, Claudia Polloni, Francesco Alesiani, Massimo Catarini, Sagar Lonial, Giorgio Santoni, Claudio Cardinali and Maria Beatrice Morelli and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Silvia Gentili

32 papers receiving 437 citations

Peers

Silvia Gentili
Robert J Markelewicz United States
Julie Errington United Kingdom
Adrian Stecuła United States
Silvia Gentili
Citations per year, relative to Silvia Gentili Silvia Gentili (= 1×) peers Guowei Dai

Countries citing papers authored by Silvia Gentili

Since Specialization
Citations

This map shows the geographic impact of Silvia Gentili's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Gentili with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Gentili more than expected).

Fields of papers citing papers by Silvia Gentili

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Gentili. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Gentili. The network helps show where Silvia Gentili may publish in the future.

Co-authorship network of co-authors of Silvia Gentili

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Gentili. A scholar is included among the top collaborators of Silvia Gentili based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Gentili. Silvia Gentili is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Joseph, Nisha S., Silvia Gentili, Jonathan L. Kaufman, Sagar Lonial, & Ajay K. Nooka. (2017). High-risk Multiple Myeloma: Definition and Management. Clinical Lymphoma Myeloma & Leukemia. 17. S80–S87. 32 indexed citations
2.
Offidani, Massimo, et al.. (2017). Stem Cell Transplantation in Multiple Myeloma. Current Cancer Drug Targets. 17(9). 769–781. 1 indexed citations
3.
Gramatzki, Martin, Andreas Günther, Massimo Offidani, et al.. (2016). Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study. Blood. 128(22). 3334–3334. 5 indexed citations
4.
Gentile, Massimo, Massimo Offidani, Ernesto Vigna, et al.. (2015). Ixazomib for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs. 24(9). 1287–1298. 41 indexed citations
5.
Gentile, Massimo, Massimo Offidani, Ernesto Vigna, et al.. (2015). Smoldering multiple myeloma: to treat or not to treat. Expert Opinion on Pharmacotherapy. 16(6). 785–790. 4 indexed citations
6.
Offidani, Massimo, et al.. (2015). Oral ixazomib maintenance therapy in multiple myeloma. Expert Review of Anticancer Therapy. 16(1). 21–32. 7 indexed citations
7.
Offidani, Massimo, et al.. (2014). An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. OncoTargets and Therapy. 7. 1793–1793. 45 indexed citations
8.
Gentili, Silvia & Sagar Lonial. (2014). Relapsed and Refractory Multiple Myeloma. Hematology/Oncology Clinics of North America. 28(5). 861–890. 6 indexed citations
9.
Palombo, Marco, Silvia Gentili, Marco Bozzali, Emiliano Macaluso, & Silvia Capuani. (2014). New insight into the contrast in diffusional kurtosis images: Does it depend on magnetic susceptibility?. Magnetic Resonance in Medicine. 73(5). 2015–2024. 19 indexed citations
10.
Offidani, Massimo, Claudia Polloni, Federica Cavallo, et al.. (2012). Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leukemia & lymphoma. 53(9). 1722–1727. 41 indexed citations
11.
Offidani, Massimo, Laura Corvatta, Claudia Polloni, et al.. (2012). Assessment of Vulnerability Measures and Their Effect on Survival in a Real-Life Population of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry. Clinical Lymphoma Myeloma & Leukemia. 12(6). 423–432. 36 indexed citations
12.
Offidani, Massimo, Laura Corvatta, Claudia Polloni, et al.. (2011). Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide. Leukemia & lymphoma. 52(5). 776–785. 17 indexed citations
13.
Offidani, Massimo, Laura Corvatta, Claudia Polloni, et al.. (2011). Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed–refractory multiple myeloma. Annals of Hematology. 90(12). 1449–1456. 14 indexed citations
14.
Spina, Francesco, Vittorio Montefusco, Claudia Crippa, et al.. (2011). Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. Leukemia & lymphoma. 52(7). 1262–1270. 9 indexed citations
15.
Offidani, Massimo, Claudia Polloni, Laura Corvatta, et al.. (2011). Assessment of Frailty Measures and Their Effect on Survival in a Population of Patients Registered At Marche Region Multiple Myeloma (MM) Registry. Blood. 118(21). 2873–2873. 1 indexed citations
16.
Offidani, Massimo, Pietro Leoni, Laura Corvatta, et al.. (2010). ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma. European Journal Of Haematology. 84(6). 474–483. 12 indexed citations
17.
Offidani, Massimo, Pietro Leoni, Laura Corvatta, et al.. (2010). Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials. Clinical Lymphoma Myeloma & Leukemia. 10(5). 353–360. 2 indexed citations
18.
Offidani, Massimo, Pietro Leoni, Sara Bringhen, et al.. (2010). Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. Leukemia & lymphoma. 51(8). 1444–14449. 4 indexed citations
19.
Offidani, Massimo, Laura Corvatta, Claudia Polloni, et al.. (2008). Thalidomide‐dexamethasone versus Interferon‐alpha‐dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. British Journal of Haematology. 144(5). 653–659. 23 indexed citations
20.
Cangemi, Vincenzo, P Volpino, Silvia Gentili, et al.. (1997). Carcinoma of the duodenum: management and survival in 14 cases.. PubMed. 39(1). 24–9. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026